Bliss Gvs Pharma Limited, a active public limited company, was established on 11 December 1984 in Mumbai, Maharashtra, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: L24230MH1984PLC034771. Registered under ROC Roc Mumbai. it is listed on BSE: 506197 and NSE: BLISSGVS. It has an authorized capital of ₹15.00 Cr and a paid-up capital of ₹10.57 Cr.
Formerly known as Bliss Gvs Phrma Limited (Cn), Bliss Chemicals And Pharmaceuticals India Limited. It upholds a compliant status. In 2024, it reported revenue of ₹638.96 Cr and a net worth of ₹988.44 Cr. Employing 926 professional, Its leadership includes Vibha Gagan Sharma (Whole-Time Director), Santosh Laxman Parab (Director), Nandkumar Kashinath Chodankar (Director). Past directors included Vipul Babulal Thakkar, Narsimha Shibroor Kamath, Vibha Gagan Sharma. It holds ₹261.00 Cr open charges and ₹301.25 Cr settled loans. Its latest AGM occurred on 31 July 2025, with the balance sheet filed on 31 March 2025. It is based at 102, Hyde Park, Sakivihar Road, Andheri (East)., Mumbai, Maharashtra, 400072.
L24230MH1984PLC034771
034771
11 December 1984
₹15.00 Cr
₹10.57 Cr
Roc Mumbai
Listed (BSE: 506197, NSE: BLISSGVS)
Active
Explore comprehensive insights into Bliss Gvs Pharma Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vibha Gagan Sharma | Whole-Time Director | 29 Jul 2008 | Current |
| Santosh Laxman Parab | Director | 24 May 2016 | Current |
| Nandkumar Kashinath Chodankar | Director | 22 Jun 2024 | Current |
| Gagan Sharma Harsh | Managing Director | 21 Jan 2021 | Current |
| Shilpa Bhatia | Director | 11 Feb 2020 | Current |
| Shruti Vishal Rao | Whole-Time Director | 27 Jul 2006 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Cfo(Kmp) | 14 Aug 2020 | Past |
| Pramod Abcsdd | Managing Director | 11 May 2021 | Past |
| Pramod Abcsdd | Director | 27 Jan 2010 | Past |
| Pramod Abcsdd | Additional Director | 14 Sep 2016 | Past |
| Pramod Abcsdd | Additional Director | 24 Jul 2024 | Past |
| Pramod Abcsdd | Additional Director | 11 May 2021 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Bliss Gvs Pharma Limited, for the financial year ended 2024, experienced Minor drop in revenue, with a 1.56% decrease. The company also saw a substantial fall in profitability, with a 40.75% decrease in profit. The company's net worth moved up by a moderate rise of 5.49%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Bliss Gvs Pharma had a promoter holding of 35.04% and a public holding of 64.96%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹2,610,000,000.00
₹3,012,483,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Dec 2023 | Others | ₹35.00 Cr | Open |
| 02 Sep 2023 | Others | ₹75.00 Cr | Open |
| 17 Sep 2021 | Others | ₹65.00 Cr | Open |
| 21 Nov 2020 | Hdfc Bank Limited | ₹1.00 Cr | Open |
| 07 Oct 2006 | Others | ₹85.00 Cr | Open |
Explore comprehensive loan charge details -
Bliss Gvs Pharma has a workforce of 926 employees as of Mar 31, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Bliss Gvs Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bliss Gvs Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Narsimha Shibroor Kamath was appointed as a Ceo was appointed as a Ceo on 10 Oct 2025 & has been associated with this company since 1 month 14 days . was completed.
Progress on Bliss Gvs Pharma Limited last Annual general meeting of members was held on 31 Jul 2025 as per latest MCA records. was documented.
Progress on Bliss Gvs Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai. was documented.
The activity A charge with Others of Rs. 75.00 Cr registered on 02 Sep 2023 with Charge ID 100791236 was modified on 30 Jan 2025. was completed.
The activity Nandkumar Kashinath Chodankar was appointed as a Director was appointed as a Director on 22 Jun 2024 & has been associated with this company since 1 year 5 months . was completed.
Progress on A charge with Others of Rs. 35.00 Cr registered on 16 Dec 2023 with Charge ID 100843177 was modified on 22 Dec 2023. was documented.
"The successful audit outcome from USFDA is a reflection of the steady progress that we are making into the mature pharma markets," Bliss GVS Pharma VP-Strategy & Business Development Gagan Harsh... .
"The successful audit outcome from USFDA is a reflection of the steady progress that we are making into the mature pharma markets," Bliss GVS Pharma VP-Strategy & Business Development Gagan Harsh Sharma said. .
Total income of the company increased by 4.8 per cent to Rs 253.3 crore from Rs 241.7 crore during the period under review..
The CIN of Bliss Gvs Pharma Limited is L24230MH1984PLC034771.
Bliss Gvs Pharma Limited is headquartered at 102, Hyde Park, Sakivihar Road, Andheri (East)., Mumbai, Maharashtra, 400072.
Bliss Gvs Pharma Limited was incorporated on 11 December 1984.
The current directors of Bliss Gvs Pharma Limited are
The primary industry of Bliss Gvs Pharma Limited is Manufacturing.
Bliss Gvs Pharma Limited is listed. It is listed on BSE: 506197 and NSE: BLISSGVS.
The authorized capital of Bliss Gvs Pharma Limited is ₹15.00 Cr, and the paid-up capital is ₹10.57 Cr.
The compliance status of Bliss Gvs Pharma Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX